Crisaborole

DGAP-News: It All Comes Down To Science And Research With The Efficacy Of Jupiter Wellness’s Lineup Of Skin And Hair Treatment Drugs

Retrieved on: 
Tuesday, September 6, 2022
CBD, Pachydactylus labialis, Burns, Patient, Breast cancer, Burn, Advertising, Female, NYSE, OTC, Sexual desire, Research, Hair, NASDAQ, Amazon (company), Pfizer, PFE, Food and Drug Administration, Man, Vitiligo, Sale, Walmart, Food, Skin, Herpes labialis, Psoriasis, Pleasure, Simplex, Dermatitis, WMT, Social media, FDA, Mouth, Atopic dermatitis, Hair loss, Skin care, Intellectual property, Woman, Minoxidil, Health, Biology, AMZN, Cosmetics, Pharmaceutical industry, Petroleum jelly, Dietary supplement, Crisaborole

Jupiter Wellness Inc. (NASDAQ: JUPW), which focuses on making drugs and skin- and hair-care products, is riding on this emerging trend.

Key Points: 
  • Jupiter Wellness Inc. (NASDAQ: JUPW), which focuses on making drugs and skin- and hair-care products, is riding on this emerging trend.
  • Jupiters development pipeline includes products to address psoriasis, eczema, burns, herpes and cold sores, hair loss and female libido loss.
  • It reportedly works by enriching the sulfotransferase enzyme in the hair and amping up the efficacy of Minoxidil for hair loss.
  • I am pleased to report that Jupiter Wellness is on track with its 2022 roadmap, Jupiter Wellness CEO Brian John said.

ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, October 26, 2021
KOL, Eli Lilly and Company, Teaching hospital, Atopic dermatitis, MD, ASLN, Research, MAD, Ferda Mravenec, Icahn School of Medicine at Mount Sinai, University, Master of Science, Anacor, Disease, CA, Eczema Area and Severity Index, Skin, Patient, EASI, DHODH, Secondary research, Intention, ADSS, Company, Crisaborole, University of California, CEO, ADS, AD, Inflammatory bowel disease, Coronavirus Scientific Advisory Board (Turkey), Nasdaq, GLOBE, Mount Sinai, SAB, Bachelor of Medical Sciences, Doctor of Philosophy, Associate, Department, ITT, Pharmaceutical industry, Medical device, Lithium

MENLO PARK, Calif. and SINGAPORE, Oct. 26, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2021, and provided an update on recent corporate activities.

Key Points: 
  • MENLO PARK, Calif. and SINGAPORE, Oct. 26, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2021, and provided an update on recent corporate activities.
  • Research and development expenses were US$5.3 million in the third quarter of 2021 compared to US$2.2 million in the third quarter of 2020.
  • General and administrative expenses were US$2.8 million in the third quarter of 2021 compared to US$1.3 million in the third quarter of 2020.
  • Net loss for the third quarter of 2021 was US$8.6 million compared to a net loss of US$3.5 million for the third quarter of 2020.

Imre Welcomes Bria Rooney as Newest Leader Strengthening Earned Media Expertise

Retrieved on: 
Wednesday, September 15, 2021
Health, NGLCC, Dickies, Aspirin/paracetamol/caffeine, GSK, Broach, Bausch & Lomb, Imre, Marketing, NFL, McCormick, Consumer, Habit, View, Public relations, PR, Airstream, Growth, Multimedia, Senior, Intelligence, Crisaborole, Data Analytics Acceleration Library, Pulse, Social media, AstraZeneca, Leadership, Management

NEW YORK, Sept. 15, 2021 /PRNewswire/ --Imre expands its focus on earned activation with the addition of Bria Rooney as Vice President of Public Relations.

Key Points: 
  • NEW YORK, Sept. 15, 2021 /PRNewswire/ --Imre expands its focus on earned activation with the addition of Bria Rooney as Vice President of Public Relations.
  • "Bria's track record bolsters our approach to earned activation and specifically how we think differently with our client partners to continue delivering next-level earned attention and brand belief."
  • At imre, Bria steps into a team of earned media specialists where she will be responsible for new campaign strategy leadership as well as team development and business growth.
  • Driven by innovation, the agency's integrated suite of marketing communications services include brand strategy, creative, digital marketing, social media, public relations and media, data & analytics.

Global Atopic Dermatitis Drugs Market 2021-2026 by Drug Class, Route of Administration, Geography, Competitive Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, August 20, 2021
Health, Pharmaceutical, Dupilumab, CAGR, Atopic dermatitis, Sanofi, Bayer, Principia, Growth, Geography, Adoption, Administration, Incidence, Route of administration, Government, Crisaborole, Disease, Plasma protein binding, Food, Awareness, Lists of countries and territories, USD, Allergy, Patent, Pharmaceutical industry

The Global Atopic Dermatitis Drugs Market is estimated to be USD 7.2 Bn in 2021 and is expected to reach USD 10 Bn by 2026, growing at a CAGR of 6.8%.

Key Points: 
  • The Global Atopic Dermatitis Drugs Market is estimated to be USD 7.2 Bn in 2021 and is expected to reach USD 10 Bn by 2026, growing at a CAGR of 6.8%.
  • The major factor driving the growth of the global atopic dermatitis drugs market is the growing incidence of food allergies exacerbating atopic dermatitis, increasing emphasis on systematic therapies, increasing pharmacological products in developing countries, and the rise in awareness regarding the availability of treatments for the disease.
  • Furthermore, the rising adoption of targeted treatments such as Eucrisa and Dupixent is propelling the market.
  • By Drug Class, the market is classified into biologics, calcineurin inhibitors, corticosteroids, and pde4 inhibitors.

U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis

Retrieved on: 
Tuesday, March 24, 2020
Biotechnology, General Health, FDA, Health, Pharmaceutical, Medical specialties, Steroids, Chemistry, Type I hypersensitivity, RTT, Corticosteroids, Atopic dermatitis, Crisaborole, Atopy, Dermatitis, Dupilumab, Amcinonide, the CrisADe CARE 1 Study, Atopic Dermatitis, EUCRISA® (crisaborole) ointment, 2%

"The approval of a steroid-free treatment option for this age group offers potential relief for these very young patients."

Key Points: 
  • "The approval of a steroid-free treatment option for this age group offers potential relief for these very young patients."
  • EUCRISA may cause side effects including allergic reactions at or near the application site.
  • EUCRISA is a prescription ointment used on the skin (topical) to treat mild-to-moderate eczema (atopic dermatitis) in adults and pediatric patients 3 months of age and older.
  • 2Pfizer Inc. Pfizer Receives FDA Approval for EUCRISA (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema).

Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis

Retrieved on: 
Monday, July 1, 2019
Children, Biotechnology, Other Health, Pharmaceutical, Consumer, Health, General Health, RTT, Chemistry, Type I hypersensitivity, Medical specialties, Immunology, Crisaborole, Ethers, Atopic dermatitis, Dermatitis, Atopy, Anti-inflammatory, Anacor, the CrisADe CARE 1 Study, Atopic Dermatitis, Crisaborole

Pfizer Inc. (NYSE:PFE) today announced top-line results from a Phase 4 study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema.

Key Points: 
  • Pfizer Inc. (NYSE:PFE) today announced top-line results from a Phase 4 study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema.
  • These results add to the growing body of evidence that underscores the strength of data for crisaborole as a steroid-free, topical treatment option for people with mild to moderate atopic dermatitis.
  • At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
  • Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis.

EUCRISA™ (crisaborole) Now Available in Canada

Retrieved on: 
Wednesday, November 7, 2018
RTT, Type I hypersensitivity, Immunology, Chemistry, Organic chemistry, Atopic dermatitis, Crisaborole, Pfizer, Dermatitis, Atopy

KIRKLAND, QC, Nov. 7, 2018 /CNW/ - Pfizer Canada has announced that Health Canada has approved EUCRISA (crisaborole), and that it is now available in Canada.

Key Points: 
  • KIRKLAND, QC, Nov. 7, 2018 /CNW/ - Pfizer Canada has announced that Health Canada has approved EUCRISA (crisaborole), and that it is now available in Canada.
  • The approval of EUCRISA provides an important new treatment option for the care of children and adults with mild to moderate atopic dermatitis."
  • "Pfizer Canada understands the significant challenges associated with treating atopic dermatitis," says Vratislav Hadrava, Chief Medical Officer, Pfizer Canada.
  • To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/PfizerCanada).